This fund typically allocates a minimum of 80% of its total net assets (including any borrowed capital utilized for investment purposes) to the common stock shares of businesses within the health sciences domain. This includes companies focused on the research, development, manufacturing, or distribution of offerings related to healthcare, medicine, or the broader life sciences. While the portfolio has the liberty to invest in companies of any market capitalization, most of its holdings are projected to be in large- and medium-sized corporations. The fund operates as a non-diversified investment vehicle.